Assembly Biosciences, Inc. (ASMB) Investment Analysis
1. Executive Summary
Assembly Biosciences, Inc. (ASMB) represents a specialized clinical-stage biopharmaceutical entity that has undergone a fundamental strategic pivot to address high-unmet-need viral infections through the development of innovative small-molecule therapeutics. Based in South San Francisco, the company focuses on serious, chronic viral diseases, primarily targeting the herpes simplex virus (HSV), hepatitis B virus (HBV), and hepatitis delta virus (HDV).[1, 2] The organizational mission centers on shifting the treatment paradigm from simple suppression to profound viral control or functional cures, utilizing a proprietary discovery platform that prioritizes long-acting oral formulations.[3, 4]
The company generates revenue through a high-leverage collaboration model, most notably a 12-year strategic partnership with Gilead Sciences, Inc. (GILD) established in late 2023.[5] This partnership provides Assembly with significant non-dilutive capital in the form of upfront payments, research collaboration funding, and potential milestone payments, alongside equity investments from Gilead, which currently maintains a significant ownership stake.[2, 6] Revenue is primarily derived from these collaborative research services and the recognition of option fees when partners elect to license specific programs.[4, 7] Geographically, while its research and development operations are concentrated in the United States, its target end-markets are global, given the pervasive international prevalence of chronic hepatitis and recurrent herpes infections.[8, 9]
Assembly’s core product pipeline consists of several first-in-class or best-in-class small-molecule candidates:
* ABI-5366 and ABI-1179: These are long-acting helicase-primase inhibitors (HPIs) designed for the treatment of recurrent genital herpes. They represent the first significant innovation in the herpes space in over two decades.[5, 10]
* ABI-6250: An orally bioavailable entry inhibitor for chronic HDV, targeting the NTCP receptor.[1, 2]
* ABI-4334: A next-generation capsid assembly modulator (CAM) for chronic HBV, which demonstrates significantly higher potency than initial candidates in this class.[11, 12]
The primary customer types for Assembly are large pharmaceutical companies (B2B) seeking validated clinical assets to bolster their virology portfolios, while the end-user markets comprise the millions of patients suffering from chronic viral conditions. Customers and partners choose Assembly over alternatives due to the company's focus on "long-acting" small molecules, which offer the convenience of weekly or monthly oral dosing—a major improvement over current daily regimens or injectable alternatives.[5, 13, 14] This therapeutic differentiation addresses the "pill burden" and compliance issues that often lead to viral breakthrough in traditional therapies.[9, 13]
Strategic Virology Play
2. Business Drivers & Strategic Overview
The economic and strategic engine of Assembly Biosciences is driven by its ability to translate deep virology expertise into clinical-stage assets that solve the convenience and efficacy limitations of existing standards of care. The company’s strategic outlook is inextricably linked to its 12-year collaboration with Gilead Sciences, which provides the financial stability and commercial infrastructure necessary to advance complex virology programs.[4, 5]
Product Detail and Clinical Mechanism
The company's primary focus is on small-molecule inhibitors, which offer logistical advantages over biologics, such as oral administration and ambient temperature stability.
Helicase-Primase Inhibitors (HPIs) for HSV
The HPI program, comprising ABI-5366 and ABI-1179, targets the replication machinery of the herpes simplex virus. Current nucleoside analogs like valacyclovir work by inhibiting DNA polymerase, but they are limited by short half-lives and an inability to adequately suppress viral shedding, which occurs between symptomatic outbreaks.[8, 13] Assembly’s HPIs block the helicase-primase enzyme complex, which is essential for DNA unwinding and primer synthesis.[5, 15]
Phase 1b data has shown that these molecules can achieve over 90% reductions in viral shedding rates.[13] For example, in clinical cohorts evaluating ABI-1179, a 50 mg weekly dose resulted in a 98% reduction in the HSV-2 shedding rate compared to placebo.[13] The "long-acting" nature of these molecules allows for once-weekly or potentially once-monthly dosing, which is a transformative shift from the daily requirement of current therapies.[2, 5]
Hepatitis Delta Virus (HDV) Entry Inhibitors
ABI-6250 is an oral small-molecule entry inhibitor that blocks the sodium taurocholate cotransporting polypeptide (NTCP) receptor on the surface of liver cells.[1, 2] This receptor is the required entry point for both HBV and HDV. By blocking this gateway, ABI-6250 prevents the virus from infecting new hepatocytes, which is critical for reducing the viral load in chronic HDV patients.[1] This program is strategically positioned as an oral alternative to Gilead’s Hepcludex (bulevirtide), which currently requires daily subcutaneous injections.[16]
Next-Generation Capsid Assembly Modulators (CAMs)
ABI-4334 represents the "next generation" of HBV CAMs, designed with picomolar potency.[12, 17] Unlike earlier CAMs that primarily targeted the assembly of the viral capsid, ABI-4334 is designed to inhibit both capsid assembly and the formation of covalently closed circular DNA (cccDNA), the genetic reservoir that allows HBV to persist in the liver.[1, 12] Although Gilead declined to exercise its option on this asset in 2026, Assembly has regained full rights and is pursuing a new partnership, citing its potent clinical profile—including multi-log declines in HBV DNA and pgRNA—as a significant asset for any "functional cure" combination regimen.[2, 11, 18]
Moat and Competitive Advantage
Assembly’s moat is built on a foundation of intellectual property, regulatory expertise, and strategic partnership.
- Intellectual Property (IP): The company's patent portfolio is focused on specific chemical modifications that enable "long-acting" pharmacokinetics. In the HPI space, Assembly has filed patents for 1,3-disubstituted tetrahydropyrimidin-2(1H)-one derivatives, which utilize an alkylene linkage to bridge urea nitrogens, a modification that enhances both the half-life and the potency of the molecules over previous "urea series" inhibitors.[15, 19]
- Cost and Ecosystem Advantages: Through the Gilead collaboration, Assembly avoids the massive capital expenditures associated with Phase 3 clinical trials and global commercialization for its licensed programs. Gilead assumes the "sole right and responsibility" for late-stage development of the HSV assets.[3, 4] This allows Assembly to operate with a much smaller headcount and lower burn rate than a traditional integrated biotech.
- Validation and Scale: The 12-year commitment from a virology leader like Gilead serves as a powerful validation of Assembly's discovery engine. This "ecosystem" advantage makes it easier for the company to attract top-tier scientific talent and potential future partners for its remaining wholly-owned assets like ABI-6250.[1, 5]
Market Opportunity and TAM Analysis
The market opportunity for Assembly is defined by the massive global prevalence of its target viruses and the lack of innovation in these spaces over recent decades.
- Genital Herpes (HSV): The global market for genital herpes treatment is valued at approximately \$2.63 billion in 2024 and is projected to grow to \$3.96 billion by 2036.[8, 20] With roughly 491 million people globally infected with HSV-2, and hundreds of millions more with HSV-1, the demand for more effective, long-acting suppression is substantial.[8, 21]
- Hepatitis Delta (HDV): HDV affects approximately 12 million people worldwide and is the most severe form of chronic viral hepatitis.[22, 23] The market is expected to grow as diagnosis rates improve, with projections reaching \$0.93 billion by 2030.[22]
- Hepatitis B (HBV): The HBV therapeutic market is expected to reach \$10.2 billion by 2035.[24] As the industry moves toward "functional cures," highly potent CAMs like ABI-4334 will be essential components of combination therapies.[12, 24]
Competitive Landscape
Assembly faces competition from traditional generic manufacturers and innovative biotech firms.
- HSV Competitors: The primary competition is generic valacyclovir (Valtrex).[20] Innovative competition includes Moderna's mRNA-1608 vaccine and GSK’s therapeutic vaccine programs.[8, 14] However, Assembly's oral small molecules are positioned to offer more reliable suppression of viral shedding compared to the early-stage data seen in current vaccine candidates.[13, 14]
- HDV Competitors: The current standard of care is Gilead’s injectable bulevirtide.[16] Clinical-stage competitors include Vir Biotechnology and Bluejay Therapeutics, which are developing monoclonal antibodies and siRNA treatments.[23, 25] Assembly's ABI-6250 is unique in being a purely oral small molecule, a major preference for chronic patients.[26]
- HBV Competitors: This is a crowded field including Aligos Therapeutics, Arbutus Biopharma, and GSK.[24] Assembly differentiates itself through the superior potency of its next-gen CAMs compared to earlier candidates that failed to show significant cccDNA impact.[11, 12]
Assembly is currently gaining ground in the HSV space due to its partnership with Gilead and the breakthrough nature of its HPI data, while holding ground in HDV as it prepares to enter Phase 2.[2, 10, 27]
Dominant Small-Molecule Engine
3. Financial Performance & Valuation
Assembly Biosciences operates under a specialized financial profile where revenue recognition is driven by milestone achievements and collaboration funding rather than product sales.
Latest Quarterly Results (Q4 2025)
Assembly Biosciences reported its fiscal year-end and fourth-quarter 2025 results on March 19, 2026.[28, 29] The company delivered a significant financial performance that substantially exceeded market expectations.
| Metric |
Q4 2025 Actual |
Q4 2025 Consensus Estimate |
Surprise |
| Revenue |
\$42.47 Million |
\$7.42 Million |
+300.7% |
| EPS (GAAP) |
\$2.48 |
(-\$0.51) |
+586.3% |
| Net Income |
\$22.1 Million |
(-\$8.0 Million) |
N/A |
The massive revenue beat was primarily attributable to the recognition of the \$35 million net option fee from Gilead Sciences, which elected to license the HPI program for recurrent genital herpes.[2, 5] This payment represents the \$45 million gross option fee minus \$10 million in accelerated funding previously provided by Gilead in late 2024.[4]
For the full year 2025, Assembly reported a net loss of only \$6.1 million (\$0.55 per share), a dramatic narrowing from the \$40.2 million loss (\$6.69 per share) in 2024.[2] Annual revenue rose to \$72.3 million from \$28.5 million in the prior year.[2]
Key Financial Drivers and Management Guidance
- Cash Position: As of December 31, 2025, the company held \$248.1 million in cash, cash equivalents, and marketable securities.[2]
- Cash Runway: Management projects that its current capital is sufficient to fund operations into 2028.[2] This runway is a critical valuation driver as it mitigates the risk of near-term dilutive equity offerings.
- Operating Expenses: R&D expenses grew to \$64.8 million in 2025, up from \$55.9 million in 2024, driven by the intensive enrollment in Phase 1b studies for the HPI program.[2] G&A expenses remained relatively stable at \$19.6 million.[2]
- Guidance: While the company does not provide traditional revenue guidance, management highlighted that by mid-2026, they will determine whether to "opt-in" to a 40% U.S. cost/profit share for the HSV program.[2, 4] If they opt in, R&D expenses will rise significantly in exchange for much higher long-term commercial upside.
Valuation Analysis
Valuing a clinical-stage biotech like Assembly requires looking beyond current earnings multiples to the risk-adjusted Net Present Value (NPV) of its pipeline.
- Cash Valuation: With ~15.9 million shares outstanding, the company holds approximately \$15.60 per share in cash.[2, 30]
- Enterprise Value (EV): At a current share price of \$28.30, the market is attributing approximately \$200 million to the clinical pipeline and the 12-year Gilead agreement.[30, 31]
- Pipeline NPV Drivers:
- HSV Program: Assembly is eligible for up to \$330 million in future regulatory and commercial milestones, plus tiered royalties.[4, 5] Even at a conservative 20% probability of success, the risk-adjusted milestones alone are worth nearly \$4 per share.
- HDV Program: Capture of 25% of the \$0.9B HDV market with a 20% net margin and a 15x multiple would imply an additional pipeline value of \$675M, or roughly \$42 per share.[22]
Currently, the stock trades at a Price-to-Sales (P/S) ratio of 6.32 and a Price-to-Book (P/B) ratio of 2.21.[30] Analyst price targets have been revised upward following the Q4 results, with a consensus target of \$42.75 to \$46.60, representing over 50% upside from current levels.[30, 32, 33]
Undervalued Pipeline Leverage
4. Risk Assessment & Macroeconomic Considerations
Investing in Assembly Biosciences entails significant risks typical of the biotechnology sector, amplified by the binary nature of clinical trial results and the dependency on a single large-scale partnership.
Company-Specific and Execution Risks
- Clinical Trial Failure: The primary risk is that ABI-5366 or ABI-1179 may fail to demonstrate sufficient efficacy or safety in Phase 2 or Phase 3 trials. While Phase 1b data was positive, larger patient populations often reveal safety signals or lower efficacy.[1, 2]
- Partner Dependency: Assembly is heavily reliant on Gilead. If Gilead were to deprioritize virology or experience a corporate restructuring, the 12-year collaboration could be jeopardized.[4, 18] Gilead's decision to pass on the HBV asset (ABI-4334) serves as a reminder that the partnership does not guarantee the advancement of every program.[11]
- Opt-in Financial Burden: If Assembly chooses the 40% U.S. profit-share path in mid-2026, it must also fund 40% of the U.S. development costs. This would dramatically increase its cash burn and could force a capital raise sooner than the current 2028 projection.[2, 4]
Competitive and Industry Risks
- Disruptive Innovation: mRNA vaccines from Moderna or CRISPR-based gene editing from competitors could potentially "cure" HSV, rendering daily or weekly suppression therapies obsolete.[8]
- HBV Re-partnering Uncertainty: Regaining the rights to ABI-4334 is only a win if Assembly can find a new partner. If no partner is found, the asset may be discontinued, leading to a write-down of its perceived value.[2, 11]
Regulatory and Macroeconomic Risks
- FDA Scrutiny: The FDA has become increasingly cautious regarding long-acting suppressive therapies. Any requirement for extended long-term safety studies (e.g., 2-year carcinogenicity data) before approval could delay the launch of the HPI program by several years.
- Interest Rate Sensitivity: As a company whose primary cash flows are projected many years into the future, Assembly's valuation is highly sensitive to interest rates. Higher rates lead to a higher discount rate for future royalties, significantly lowering the current stock's fair value.
- Drug Pricing Reform: The Inflation Reduction Act (IRA) and potential future legislation could limit the pricing power of breakthrough antivirals, particularly in the HBV and HDV spaces where government-funded programs are major payers.[22, 24]
Risk Hierarchy
| Risk Type |
Early Warning Sign |
Impact on Thesis |
| Clinical |
Breakthrough shedding in Phase 2 long-duration cohorts. |
Critical: Destroys the primary bull case for the HPI program. |
| Strategic |
Failure to secure a partner for ABI-4334 by end of 2026. |
Moderate: Signals lack of industry interest in CAM mechanism. |
| Financial |
Decision to opt into 40% profit share followed by a secondary offering. |
High: Immediate dilution for long-term (uncertain) gain. |
Binary Clinical Risks
5. 5-Year Scenario Analysis
Predicting the share price for ASMB in 2031 requires making assumptions about the success of the HPI and HDV programs.
High Case: The "Virology Leader" Outcome
- Key Fundamentals: Both ABI-5366 (HSV) and ABI-6250 (HDV) successfully reach the market. Assembly opts into the 40% U.S. profit share for HSV, and the market adoption is rapid due to the weekly dosing advantage. A new partner is found for HBV, generating \$500M in cumulative milestones by 2031.
- Revenue (Year 5): \$520 Million (Milestones + 40% U.S. HSV profits + 15% Int'l HSV royalties + HDV royalties).
- Valuation Assumptions: 55% Net Margin. 20x Price-to-Earnings multiple.
- Share Count: 18.5 Million (accounting for RSU vesting and minor dilution).
- Projected Price: \$309.00
Base Case: The "Partnered Royalty" Outcome
- Key Fundamentals: The HSV program is successfully launched, but Assembly chooses the lower-risk "royalty and milestone" path instead of the 40% profit share to preserve cash. HDV program is partnered with a mid-size pharma. HBV program is shelved.
- Revenue (Year 5): \$180 Million (Annualized royalties from HSV launch + R&D funding + HDV milestones).
- Valuation Assumptions: 40% Net Margin. 6x Revenue multiple.
- Share Count: 16.8 Million.
- Projected Price: \$64.25
Low Case: The "Clinical Setback" Outcome
- Key Fundamentals: The HPI program fails to meet its primary endpoint in Phase 3. Gilead terminates the collaboration. HDV program continues but faces delays and competition from generics.
- Revenue (Year 5): \$15 Million (Interest income + minor licensing).
- Valuation Assumptions: Negative margins. Valued at 0.8x Cash-on-hand.
- Share Count: 24 Million (significant dilution required to fund ongoing operations).
- Projected Price: \$1.50
5-Year Scenario Summary Table
| Scenario |
Revenue Year 5 (2031) |
Margin / Earnings Assumption |
Valuation Multiple |
Current Price |
Implied Future Price |
5-Year Total Return |
Annualized Return |
Probability |
| High Case |
\$520.0M |
55% / \$286M Net |
20x P/E |
\$28.30 |
\$309.18 |
+992.5% |
61.2% |
15% |
| Base Case |
\$180.0M |
40% / \$72M Net |
6x P/S |
\$28.30 |
\$64.28 |
+127.1% |
17.8% |
55% |
| Low Case |
\$15.0M |
(-\$40M) Net |
0.8x Cash |
\$28.30 |
\$1.50 |
-94.7% |
-44.2% |
30% |
Probability Weighted Price Target: \$82.19
Asymmetric Risk-Reward
6. Qualitative Scorecard
Rating scale: 1 (Lowest) to 10 (Highest).
- Management Alignment: 8/10
Management is well-aligned through a new 2026 Corporate Bonus Plan that ties up to 75% of the CEO's base salary to performance-based outcomes.[34] Furthermore, Gilead’s 29% ownership and board representation ensure oversight from a sophisticated strategic partner.[6]
- Revenue Quality: 6/10
Current revenue is high-quality in terms of credit risk (Gilead), but it is primarily non-recurring milestone/option income.[2, 4] Long-term royalty streams have yet to be established.
- Market Position: 8/10
Assembly holds a dominant mindshare in "long-acting oral" candidates. In the HSV space, they are the only clinical-stage company with positive HPI data for weekly/monthly dosing.[10, 13]
- Growth Outlook: 9/10
The total addressable markets for HSV and HBV are in the billions of dollars. The potential for a "functional cure" in HBV and a "preferred oral" in HDV represents massive latent growth.[8, 24]
- Financial Health: 9/10
With \$248M in cash and no debt, Assembly’s balance sheet is a fortress compared to most of its micro-cap biotech peers.[2]
- Business Viability: 7/10
The business is highly viable through 2028 based on current cash. The long-term viability depends entirely on clinical success and the durability of the Gilead partnership.[2, 5]
- Capital Allocation: 5/10
Historical dilution has been significant (share count doubled in 12 months).[2, 35] However, the strategic decision to partner early with Gilead has successfully offloaded hundreds of millions in R&D costs.
- Analyst Sentiment: 9/10
Analysts are overwhelmingly positive, with 86% Buy ratings and targets as high as \$65 per share.[33, 36]
- Profitability: 2/10
Aside from the accounting profit in Q4 2025, the company is fundamentally loss-making and is not expected to be sustainably profitable until at least 2029.[35, 37]
- Track Record: 4/10
The company has a history of clinical resets (e.g., vebicorvir). The current management team must prove they can bring an asset to market to improve this score.[18, 35]
Overall Blended Score: 6.7 / 10
High-Quality Speculation
7. Conclusion & Investment Thesis
Assembly Biosciences stands at a pivotal juncture. The company has successfully transitioned from a failed first-generation HBV candidate to a robust, validated, and long-acting antiviral platform. The cornerstone of the investment thesis is the Gilead Sciences collaboration, which provides \$248.1 million in cash, validates the scientific approach, and covers the majority of late-stage clinical expenses for the lead HSV program.[2, 4, 5]
Key catalysts for the next 18 months include the mid-2026 opt-in decision for the HSV program, the initiation of Phase 2 trials for HDV (ABI-6250), and the potential for a new partnership for the HBV asset (ABI-4334).[2, 27] While clinical failure remains a pervasive risk, the current valuation effectively treats the clinical pipeline as a free "call option" given the high cash balance per share.[30, 31] For investors willing to tolerate binary outcomes, Assembly offers a rare combination of top-tier pharmaceutical validation and micro-cap growth potential.
Leveraged Call Option
8. Technical Analysis, Price Action & Short-Term Outlook
ASMB's technical profile is currently in a period of consolidation. The stock is trading at \$28.30, which is just below its 200-day moving average of \$28.63.[31, 38] Short-term support is found at \$27.66, while resistance levels sit at \$28.75.[39] The RSI of 39.3 indicates the stock is nearing an oversold condition, which could lead to a short-term bounce as the market digests the recent Q4 beat.[38] The short-term outlook is neutral until the stock breaks above the 200-day MA.
Consolidating Below Resistance
- Form 10-K for Assembly Biosciences INC filed 03/20/2025, https://investor.assemblybio.com/static-files/7a2cb867-28e4-4d65-ba04-fca27c7d06fc
- Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights, https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-year-end-2025-financial-results-and
- Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026, https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-highlights-presentations-positive-phase-1b
- Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes, https://investor.assemblybio.com/news-releases/news-release-details/gilead-sciences-exercises-option-license-assembly-biosciences
- Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech, https://www.fiercebiotech.com/biotech/gilead-pays-35m-license-pair-hsv-assets-assembly-bio-pact
- ASMB SEC Filings - Assembly Bioscie 10-K, 10-Q, 8-K Forms - Stock Titan, https://www.stocktitan.net/sec-filings/ASMB/page-3.html
- Press Releases - Investor Relations : Assembly Biosciences, Inc., https://investor.assemblybio.com/press-releases
- Genital Herpes Treatment Market Trends 2026 to 2036 - Future Market Insights, https://www.futuremarketinsights.com/reports/genital-herpes-treatment-market
- Herpes Treatment Market Size to Hit USD 3.92 Billion by 2035 - Precedence Research, https://www.precedenceresearch.com/herpes-treatment-market
- Assembly Biosciences, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, https://synapse.patsnap.com/organization/ba089da23fd6ddb69b2a3b4700dfdd8f
- Gilead turns down Assembly's ph. 1-stage HBV antiviral - Fierce Biotech, https://www.fiercebiotech.com/biotech/gilead-turns-down-chance-take-assemblys-phase-1-stage-hbv-antiviral
- Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting, https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-presents-positive-phase-1b-data-next
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of, https://investor.assemblybio.com/node/14206/pdf
- ABI-5366 - Drug Targets, Indications, Patents - Patsnap Synapse, https://synapse.patsnap.com/drug/257c15c8dbc34487a81e9d9195be9595
- Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc - PubMed, https://pubmed.ncbi.nlm.nih.gov/40830081/
- Hepatitis D Therapeutics Market Size, Share, Forecast to 2034 - Fortune Business Insights, https://www.fortunebusinessinsights.com/hepatitis-d-therapeutics-market-114768
- Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates, https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-second-quarter-2025-financial
- Assembly Biosciences (ASMB) - Trefis, https://www.trefis.com/data/companies/ASMB
- Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc | Request PDF - ResearchGate, https://www.researchgate.net/publication/394729981_Evaluation_of_the_patent_portfolio_for_helicase-primase_inhibitor_ABI-5366_of_Assembly_Biosciences_Inc
- Genital Herpes Treatment Market Size, Share & Trends | Industry Report, 2033, https://straitsresearch.com/report/genital-herpes-treatment-market
- Herpes Simplex Virus Treatment Market Analysis | Industry Growth, Size & Forecast Report, 2031 - Mordor Intelligence, https://www.mordorintelligence.com/industry-reports/herpes-simplex-virus-treatment-market
- Hepatitis D Market Report 2026, Industry Trends Forecast 2035, https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
- Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight - PR Newswire, https://www.prnewswire.com/news-releases/chronic-hepatitis-d-market-poised-for-significant-growth-during-the-forecast-period-20252034-as-emerging-therapies-drive-optimism--delveinsight-302673525.html
- Hepatitis B Therapeutics Market Profit-Sources Report 2026 to 2035 - Insightace Analytic, https://www.insightaceanalytic.com/report/hepatitis-b-therapeutics-market/3425
- Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones, https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Provides-Updates-on-Chronic-Hepatitis-Delta-and-Oncology-Programs-and-Upcoming-2026-Clinical-Milestones/default.aspx
- Assembly Biosciences (ASMB) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/asmb/forecast-price-target
- Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights, https://natlawreview.com/press-releases/assembly-biosciences-reports-year-end-2025-financial-results-and-recent
- Assembly Biosciences (ASMB) Earnings Date and Reports 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/ASMB/earnings/
- Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates - March 19, 2026, https://www.zacks.com/stock/news/2886937/assembly-biosciences-asmb-q4-earnings-and-revenues-top-estimates
- Assembly Biosciences (ASMB) Stock Price, News & Analysis - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/ASMB/
- Stock Information - Investor Relations : Assembly Biosciences, Inc., https://investor.assemblybio.com/stock-information
- ASMB: Assembly Biosciences - Full Company Report - Zacks.com, https://www.zacks.com/stock/research/ASMB/company-reports
- Assembly Biosciences (ASMB) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/ASMB/forecast/
- Assembly Biosciences (ASMB) boosts CEO bonus target in 2026 plan, https://www.stocktitan.net/sec-filings/ASMB/8-k-assembly-biosciences-inc-reports-material-event-b1b379271b3a.html
- Assembly Biosciences (Nasdaq:ASMB) - Stock Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asmb/assembly-biosciences
- ASSEMBLY BIOSCIENCES INC (ASMB) Forecast, Price Target & Analyst Ratings - ChartMill, https://www.chartmill.com/stock/quote/ASMB/analyst-ratings
- Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asmb/assembly-biosciences/news/assembly-biosciences-asmb-quarterly-profit-of-us221-million
- ASMB Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/ventrus-bioscienc-technical
- Assembly Biosciences Stock Price Forecast. Should You Buy ASMB? - StockInvest.us, https://stockinvest.us/stock/ASMB